Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin

Abstract

Epoetin alfa demonstrated a survival advantage in both of the critically ill trauma patient cohorts of two prospective, randomized clinical trials, which was not affected by baseline factors including trauma-specific variables. A definitive study in trauma subjects is warranted.